Arrowhead Pharmaceuticals, Inc. (ARWR) Cash Flow Statement

The conversion of net income to operating cash flow is erratic, with 2025Q2 showing OCF/NI of 1.24 on a $370.4M profit, while 2026Q2 shows a negative ratio on a loss. This suggests that working capital changes, particularly receivables from milestone payments, drive cash flow more than underlying operations. Investors should monitor the sustainability of these swings, as they may indicate that reported earnings are not a reliable indicator of cash generation.

The FCF trajectory is dominated by episodic milestone receipts, with 2025Q2's $454.8M FCF contrasting sharply with the $181.3M burn in 2026Q3. This pattern suggests that the company's cash generation is not yet self-sustaining, and the negative FCF in most quarters implies ongoing reliance on external funding. The FCF margin of -2.4% in 2026Q3, despite a revenue base, underscores the underlying cash burn when milestone income is absent.

CapEx remains modest, never exceeding $34.1M in the reported quarters, which suggests that the company's growth is not constrained by physical asset investment. However, the low CapEx relative to revenue implies that the business model relies on intangible assets and human capital, with R&D expenses (not captured in CapEx) driving the cash burn. This may indicate that the company is investing in pipeline development rather than manufacturing capacity.

The working capital line is highly volatile, with a $198.9M positive change in 2026Q2 and a -$137.2M negative change in 2026Q3. This pattern suggests that the company's cash flow is heavily influenced by the timing of milestone payments and related receivables, rather than steady operational improvements. Investors should monitor the company's ability to manage these swings, as they may indicate a reliance on a few large partners.

The absence of buybacks and minimal dividends indicates that the company is preserving cash for R&D and operational needs. The $38.4M dividend in 2026Q3 is unusual and may be a one-time event, but it does not signal a shift toward shareholder returns. Given the persistent negative FCF in most quarters, the company appears to be in a capital accumulation phase, likely to fund future clinical trials and pipeline expansion.

The cumulative gap between net income and operating cash flow is substantial, with operating cash flow being significantly less negative than net income. This divergence is likely due to non-cash items such as stock-based compensation (averaging ~$16M per quarter) and depreciation, which reduce reported earnings but do not consume cash. However, the positive divergence may also reflect favorable working capital changes, which could reverse. Investors should recognize that the company's cash burn is lower than reported losses, but the underlying trend remains negative.